Back to Library
Specialist Review

Maternal Conditions

Thalassemia in Pregnancy

Clinical review of this update pending
5 min read
Editorial update: 2026-10-20
8%–10%UAE Carrier Rate
25% (1 in 4)Inheritance Risk (Both Carriers)
11–14 WeeksCVS Window
15+ WeeksAmniocentesis Window

In brief — the direct answer

Thalassaemia is a group of inherited conditions affecting haemoglobin production. Carrier frequency varies between populations and between alpha- and beta-thalassaemia. During pregnancy, review both partners’ blood and molecular results when indicated to assess the chance of an affected child. The subtype and variant combination determine the reproductive risk and testing options.

What is Thalassemia in Pregnancy?

Thalassemia is broadly classified into two main types depending on which part of the hemoglobin molecule is affected:

  • Beta Thalassemia: Common in the region. Carriers (Beta Thalassemia Minor) usually have mild anemia but require no special treatment. If *both* parents are carriers, there is a 25% chance of the baby having Beta Thalassemia Major, a severe disease requiring lifelong blood transfusions.
  • Alpha Thalassemia: Involves the alpha globin genes. Carrying one or two silent mutations (Alpha Thalassemia Trait) is common and usually harmless. However, if a fetus inherits mutations in all four alpha genes, it leads to a critical, life-threatening condition called Hb Bart's Hydrops Fetalis, which causes severe fetal heart failure in the womb.

Who is at risk?

Couples are at risk of having a child with moderate-to-severe Thalassemia if:

  • Both partners carry the Beta Thalassemia trait (detected via hemoglobin electrophoresis showing HbA2 > 3.5%).
  • Both partners carry Alpha Thalassemia trait mutations (specifically in 'cis' configuration, which is common in Middle Eastern and Asian populations).
  • There is a known family history of Thalassemia Major or unexplained hydrops fetalis in previous pregnancies.

How we diagnose it

The diagnostic process for Thalassemia in pregnancy involves several stages:

  1. Complete Blood Count (CBC) & Hb Electrophoresis: Standard screening tools to check red blood cell size (MCV < 80 fl) and hemoglobin types. If these indices suggest Thalassemia trait, genetic sequencing is performed.
  2. Partner Testing: If the mother is a carrier, testing the father is the critical next step. If the father is not a carrier, the fetus is not at risk of severe disease.
  3. Invasive Prenatal Testing: If both parents are carriers of matching traits, we offer Chorionic Villus Sampling (CVS) at 11-14 weeks or Amniocentesis from 15 weeks to extract fetal DNA and test for the specific mutations, providing definitive diagnostic answers early in pregnancy.

What does management involve?

Management varies based on the severity and diagnosis:

  • Maternal Carriers (Thalassemia Minor): Managed with close hematological surveillance. Routine iron supplementation should be avoided unless iron deficiency is laboratory-proven, as carriers can accumulate excess iron. Higher doses of folic acid (5 mg) are typically recommended.
  • Fetus Confirmed with Thalassemia Major / Hb Bart's: If diagnosed in-utero, parents receive comprehensive MFM and pediatric counseling. In cases of Hb Bart's (Alpha Thalassemia Major), early intrauterine transfusions (IUT) can treat fetal anemia in the womb and prevent hydrops fetalis, offering a pathway to a live birth and subsequent bone marrow transplant options.

What are the outcomes?

The prognosis depends on the genetic sub-type. Children with Thalassemia Minor lead completely normal lives. For Thalassemia Major, advances in pediatric hematology, iron chelation, and bone marrow transplantation have significantly improved long-term survival and quality of life. For Alpha Thalassemia Major (Hb Bart's), without in-utero transfusion, the condition is fatal in-utero; however, early MFM diagnosis and intervention are changing these outcomes.

When to see a subspecialist

Any pregnant woman found to have microcytic anemia (low MCV) and a suspected Thalassemia trait, or couples with matching carrier states, should be referred to our MFM and genetics subspecialists immediately.

Dr. Bernard and our clinical team provide the molecular genetic testing, risk counseling, and prenatal diagnostics needed to guide you through a safe pregnancy.

Questions to ask your doctor

Thalassemia Minor (or trait) means you carry one mutated gene but have another normal gene. You are healthy and may have mild anemia. Thalassemia Major occurs when you inherit mutated genes from both parents, causing severe, symptomatic anemia.
Yes, testing the partner is crucial. If your partner is not a carrier, your baby cannot inherit Thalassemia Major. They will have at most a 50% chance of being a healthy carrier like you.
Standard Thalassemia Major cannot be detected on ultrasound. However, Alpha Thalassemia Major (Hb Bart's) causes severe fetal anemia and swelling (hydrops), which can be detected on ultrasound. Genetic testing via amniocentesis or CVS is the only way to confirm a diagnosis early.
Yes. In Vitro Fertilization (IVF) combined with Pre-implantation Genetic Testing (PGT-M) allows us to test embryos in the lab and only transfer those that do not have Thalassemia Major.

References & Clinical Guidelines

  1. Guidelines for the Management of Transfusion-Dependent β-Thalassaemia, 5th edition — Thalassaemia International Federation (2025)
  2. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: ACMG practice resource — ACMG / Genetics in Medicine (2021)
  3. Genetic testing as an integral component of Abu Dhabi premarital screening — Department of Health – Abu Dhabi (2024)
Share this resource